(Albany, USA) DelveInsight’s “Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Leptomeningeal Metastases market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Leptomeningeal Metastases market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Leptomeningeal Metastases treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Leptomeningeal Metastases market.
Request for a Free Sample Report @ Leptomeningeal Metastases Market Forecast
Some facts of the Leptomeningeal Metastases Market Report are:
- According to DelveInsight, Leptomeningeal Metastases market size is expected to grow at a decent CAGR by 2032.
- As per DelveInsight analysis, the leptomeningeal metastases market size in the 7MM was approximately USD 1.3 billion in 2021.
- Leading Leptomeningeal Metastases companies working in the market are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
- Key Leptomeningeal Metastases Therapies expected to launch in the market are Rhenium-186 NanoLiposome (186RNL), AZD1390, Paclitaxel trevatide (ANG1005), Omburtamab, and others.
- On January 2024, Plus Therapeutics announced results of a Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety, & Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered via Intraventricular Catheter for Leptomeningeal Metastases.
- On April 2023, Angiochem announced results of a Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician’s Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD).
- On March 2022, Kadmon Corporation announced results of A Phase 2, Multicenter Study of Tesevatinib in Subjects with Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases.
Leptomeningeal Metastases Overview
Leptomeningeal metastases (LM), also known as leptomeningeal carcinomatosis, occur when cancer spreads to the membranes (meninges) surrounding the brain and spinal cord. This condition typically arises from advanced-stage cancers such as breast, lung, or melanoma, though it can occur with various other malignancies. Symptoms include headaches, nausea, vomiting, neck stiffness, and neurological deficits. Diagnosis often involves imaging studies like MRI or CT scans, along with cerebrospinal fluid analysis. Treatment aims to relieve symptoms and may include intrathecal chemotherapy, radiation therapy, or targeted therapy. However, prognosis remains poor, with median survival ranging from weeks to a few months. Management focuses on palliative care and maintaining quality of life, as curative options are limited. Emerging therapies and improved supportive care strategies offer hope for better outcomes in the future.
Learn more about Leptomeningeal Metastases treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market
Leptomeningeal Metastases Market
The Leptomeningeal Metastases market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Leptomeningeal Metastases market trends by analyzing the impact of current Leptomeningeal Metastases therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Leptomeningeal Metastases market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Leptomeningeal Metastases market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Leptomeningeal Metastases market in 7MM is expected to witness a major change in the study period 2019-2032.
Leptomeningeal Metastases Epidemiology
The Leptomeningeal Metastases epidemiology section provides insights into the historical and current Leptomeningeal Metastases patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Leptomeningeal Metastases market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Leptomeningeal Metastases Epidemiology @ Leptomeningeal Metastases Market Dynamics
Leptomeningeal Metastases Drugs Uptake
This section focuses on the uptake rate of the potential Leptomeningeal Metastases drugs recently launched in the Leptomeningeal Metastases market or expected to be launched in 2019-2032. The analysis covers the Leptomeningeal Metastases market uptake by drugs, patient uptake by therapies, and sales of each drug.
Leptomeningeal Metastases Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Leptomeningeal Metastases market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Leptomeningeal Metastases Pipeline Development Activities
The Leptomeningeal Metastases report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Leptomeningeal Metastases key players involved in developing targeted therapeutics.
Key Leptomeningeal Metastases Therapies and Companies
- Rhenium-186 NanoLiposome (186RNL): Plus Therapeutics
- AZD1390: AstraZeneca
- Paclitaxel trevatide (ANG1005): Angiochem
- Omburtamab: Y-mAbs Therapeutics
Request for a sample report to understand more about the Leptomeningeal Metastases pipeline development activities @ https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market
Leptomeningeal Metastases Therapeutics Assessment
Major key companies are working proactively in the Leptomeningeal Metastases Therapeutics market to develop novel therapies which will drive the Leptomeningeal Metastases treatment markets in the upcoming years are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
Learn more about the emerging Leptomeningeal Metastases therapies & key companies @ https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market
Leptomeningeal Metastases Report Key Insights
1. Leptomeningeal Metastases Patient Population
2. Leptomeningeal Metastases Market Size and Trends
3. Key Cross Competition in the Leptomeningeal Metastases Market
4. Leptomeningeal Metastases Market Dynamics (Key Drivers and Barriers)
5. Leptomeningeal Metastases Market Opportunities
6. Leptomeningeal Metastases Therapeutic Approaches
7. Leptomeningeal Metastases Pipeline Analysis
8. Leptomeningeal Metastases Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Leptomeningeal Metastases Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Leptomeningeal Metastases Competitive Intelligence Analysis
4. Leptomeningeal Metastases Market Overview at a Glance
5. Leptomeningeal Metastases Disease Background and Overview
6. Leptomeningeal Metastases Patient Journey
7. Leptomeningeal Metastases Epidemiology and Patient Population
8. Leptomeningeal Metastases Treatment Algorithm, Current Treatment, and Medical Practices
9. Leptomeningeal Metastases Unmet Needs
10. Key Endpoints of Leptomeningeal Metastases Treatment
11. Leptomeningeal Metastases Marketed Products
12. Leptomeningeal Metastases Emerging Therapies
13. Leptomeningeal Metastases Seven Major Market Analysis
14. Attribute Analysis
15. Leptomeningeal Metastases Market Outlook (7 major markets)
16. Leptomeningeal Metastases Access and Reimbursement Overview
17. KOL Views on the Leptomeningeal Metastases Market
18. Leptomeningeal Metastases Market Drivers
19. Leptomeningeal Metastases Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting